Plasminogen Activator Inhibitor-1 and Adiponectin Are Associated With Metabolic Syndrome Components

Simple item page
dc.contributor.authorVecchiola, Andrea
dc.contributor.authorGarcia, Killen
dc.contributor.authorGonzalez-Gomez, Luis M.
dc.contributor.authorTapia-Castillo, Alejandra
dc.contributor.authorArtigas, Rocio
dc.contributor.authorBaudrand, Rene
dc.contributor.authorKalergis, Alexis M.
dc.contributor.authorCarvajal, Cristian A.
dc.contributor.authorFardella, Carlos E.
dc.date.accessioned2025-01-20T21:10:02Z
dc.date.available2025-01-20T21:10:02Z
dc.date.issued2022
dc.description.abstractBACKGROUND We aimed to study the associations of adipocytokines, endothelial damage markers, and high-sensitivity C-reactive protein (hs-CRP) with metabolic syndrome (MetS) components. METHODS This cross-sectional study included 202 subjects categorized into MetS and No-MetS according to Harmonizing Adult Treatment Panel III. RESULTS Subjects with MetS showed higher levels of proinflammatory molecules but significantly lower adiponectin levels than subjects with No-MetS. Among the studied adipocytokines, plasminogen activator inhibitor-1 (PAI-1) and adiponectin showed the strongest associations with most MetS components. PAI-1 was associated with MetS (odds ratio (OR) 1.107 (1.065-1.151), P < 0.0001), whereas adiponectin was inversely associated with MetS (OR 0.710 (0.610-0.825), P < 0.0001). Following adjustment by sex, age, body mass index, and 24-hour urinary sodium excretion in a multivariate analysis, the association of PAI-1 (OR 1.090 (1.044-1.137), P < 0.0001) and adiponectin (OR 0.634 (0.519-0.775), P < 0.0001) with MetS remained significant. Multivariate analyses supported a model in which systolic blood pressure (BP) could be predicted by PAI-1, hs-CRP, and matrix metalloproteinase 2 (R-2 = 0.125; P = 0.04); diastolic BP (R-2 = 0.218; P = 0.0001) and glucose (R-2 = 0.074; P = 0.0001) could be predicted by PAI-1; waist circumference could be predicted by PAI-1 and hs-CRP (R-2 = 0.28; P = 0.016). Receiver operating characteristic curve analysis showed that a PAI-1 concentration had the best sensitivity and specificity for discriminating subjects with MetS. CONCLUSION PAI-1 and adiponectin rendered the most robust associations with MetS components in a general population, indicating that unfavorable adipose tissue performance is a key contributor to these metabolic anomalies. Further prospective analyses should allow establishing whether these adipocytokines can anticipate the progress of MetS and cardiovascular risk.
dc.fuente.origenWOS
dc.identifier.doi10.1093/ajh/hpab138
dc.identifier.eissn1941-7225
dc.identifier.issn0895-7061
dc.identifier.urihttps://doi.org/10.1093/ajh/hpab138
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/93559
dc.identifier.wosidWOS:000777260400006
dc.issue.numero4
dc.language.isoen
dc.pagina.final318
dc.pagina.inicio311
dc.revistaAmerican journal of hypertension
dc.rightsacceso restringido
dc.subjectadipokines
dc.subjectblood pressure
dc.subjectendothelial damage
dc.subjecthypertension
dc.subjectinflammation
dc.subjectmetabolic syndrome
dc.subjectobesity
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titlePlasminogen Activator Inhibitor-1 and Adiponectin Are Associated With Metabolic Syndrome Components
dc.typeartículo
dc.volumen35
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas